Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06008288 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: May 2025 to Dec 31, 2026
    • Study completion date: Nov 2025 to Dec 31, 2027
    v6
  3. Study Identification, Study Status, Contacts/Locationsv5
  4. Lead sponsor: Jacobio Pharmaceuticals Co., Ltd. to Allist Pharmaceuticals, Inc.v4 Show 5 more changesShow less
    • Enrollment target: 69 to 88
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints revised (7)
    • Study description expanded, about 63 words
    • Study title expanded, about 10 words
  5. Study sites: 30 to 31
    • Eligibility criteria shortened, about 37 words
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 30
    • Start date changed from estimate of Nov 2023 to Oct 27, 2023
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Trial Details
NCT Number NCT06008288
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Related terms Pancreatic Neoplasms
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov